# Molecular basis to regulate the cardiac-specific form of mitochondrial phospholipid cardiolipin

> **NIH NIH K99** · JOHNS HOPKINS UNIVERSITY · 2024 · $107,298

## Abstract

Project Summary
Mitochondrial energy production in the heart is crucial for proper cardiac function due to its high energy demand.
Cardiolipin is a phospholipid localized in the inner mitochondrial membrane that is necessary for mitochondrial
energy production via oxidative phosphorylation. Consisting of two head-groups and four acyl-chains, there are
tremendous numbers of molecular species of cardiolipin with varying acyl chain compositions. Among them, the
heart enriches linoleic acid (LA)-cardiolipin. It has been suggested that the cardiac form of cardiolipin may be
patho- and physiologically significant in cardiac function by facilitating energy production. Genetic disorders of
enzymes in cardiolipin metabolism with the reduced LA-cardiolipin in the heart are accompanied by
cardiomyopathy and mitochondrial dysfunction. Also, disturbed cardiolipin profiles are observed in several
cardiac failures. However, the importance of correct cardiolipin acylation is not fully understood.
 The goal of this study is to determine the mechanisms underlying the specific regulation of cardiac
cardiolipin by reconciling three hotly debated cardiolipin acylation theories: 1) LA-cardiolipin is dependent on an
enzyme Tafazzin that remodels cardiolipin with acquired preference for LA; 2) IMM protein environment controls
cardiolipin acylation, and; 3) tissue-specific lipid pools drive cardiolipin diversity. The contribution of each theory
needs to be determined in the context of cardiac specific LA-cardiolipin. Cardiomyocytes may draw from all three
to enrich LA-cardiolipin. I will test my central hypotheses that LA-cardiolipin optimizes cardiac bioenergetics and
that cardiomyocytes have an integrated system to generate and dominantly maintain LA-cardiolipin. I will
determine the significance/preference of LA-cardiolipin in cardiac energy production (Aim 1), characterize the
contributions of the cardiac IMM protein environment in LA-cardiolipin control (Aim 2), and identify the cardiac
LA-pool and pathway that concentrates LA in cardiolipin (Aim 3).
 This study will provide a fundamental understanding of a cardiac-specific mitochondrial lipid. Also,
characterizing this heart-specific system will expand our knowledge of basic cardiac biology and energy
metabolism. Performing this study in conjunction with the proposed career development plan, including solid
mentorship and training, as well as institutional support, will develop my research-related and professional skills.
This will enable my transition toward the achievement of my career goal to become an independent investigator
who conducts phospholipid studies with multi-directional skill sets and expertise.

## Key facts

- **NIH application ID:** 10807267
- **Project number:** 1K99HL168075-01A1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Nanami Senoo
- **Activity code:** K99 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $107,298
- **Award type:** 1
- **Project period:** 2024-08-15 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10807267

## Citation

> US National Institutes of Health, RePORTER application 10807267, Molecular basis to regulate the cardiac-specific form of mitochondrial phospholipid cardiolipin (1K99HL168075-01A1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10807267. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*